Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Targeting the hepatitis B virus precore antigen with a novel IgNAR single variable domain intrabody.

Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S, Dolezal O, Griffiths K, Bartholomeusz A, Locarnini S.

Virology. 2011 Mar 1;411(1):132-41. doi: 10.1016/j.virol.2010.12.034. Epub 2011 Jan 15.

2.

Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.

Audsley J, Arrifin N, Yuen LK, Ayres A, Crowe SM, Bartholomeusz A, Locarnini SA, Mijch A, Lewin SR, Sasadeusz J.

HIV Med. 2009 Apr;10(4):229-35. doi: 10.1111/j.1468-1293.2008.00675.x. Epub 2009 Jan 28.

3.

A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics.

Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR.

Antivir Ther. 2008;13(2):161-75. Review.

PMID:
18505168
4.

Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus.

Sung JJ, Tsui SK, Tse CH, Ng EY, Leung KS, Lee KH, Mok TS, Bartholomeusz A, Au TC, Tsoi KK, Locarnini S, Chan HL.

J Virol. 2008 Apr;82(7):3604-11. doi: 10.1128/JVI.01197-07. Epub 2008 Jan 23.

5.

Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.

Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V.

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):279-82.

PMID:
18167643
6.

Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.

Revill PA, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A, Sasaduesz J, Lewin SR, Dore GJ, Matthews GV, Thio CL, Locarnini SA.

AIDS. 2007 Aug 20;21(13):1701-10.

PMID:
17690567
7.

Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors.

Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, Chen RY, Demediuk B, Shaw G, Bell SJ, Watson KJ, Locarnini SA, Desmond PV.

J Gastroenterol Hepatol. 2007 Jul;22(7):1078-85.

PMID:
17608854
8.

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C; Hepatitis B Virus Drug Resistance Working Group.

Hepatology. 2007 Jul;46(1):254-65. Review.

9.

The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.

Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T.

Antimicrob Agents Chemother. 2007 Jul;51(7):2285-92. Epub 2007 Apr 16.

10.

SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.

Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, Locarnini SA, Bartholomeusz A.

Antiviral Res. 2007 Jul;75(1):64-74. Epub 2006 Dec 22.

PMID:
17215050
11.

Genome-wide characterisation of hepatitis B mutations involved in clinical outcome.

Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F.

Heredity (Edinb). 2006 Dec;97(6):389-97. Epub 2006 Aug 9.

12.

Mutations affecting the replication capacity of the hepatitis B virus.

Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V.

J Viral Hepat. 2006 Jul;13(7):427-34. Review.

PMID:
16792535
13.

Antiviral drug resistance: clinical consequences and molecular aspects.

Bartholomeusz A, Locarnini SA.

Semin Liver Dis. 2006 May;26(2):162-70. Review.

PMID:
16673294
14.

Hepatitis B virus mutations associated with antiviral therapy.

Bartholomeusz A, Locarnini S.

J Med Virol. 2006;78 Suppl 1:S52-5.

PMID:
16622878
15.

Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.

Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL.

AIDS. 2006 Apr 4;20(6):863-70.

PMID:
16549970
16.

HBV drug resistance: mechanisms, detection and interpretation.

Shaw T, Bartholomeusz A, Locarnini S.

J Hepatol. 2006 Mar;44(3):593-606. Epub 2006 Jan 19. Review. No abstract available.

PMID:
16455151
17.

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V.

Antivir Ther. 2005;10(6):727-34.

PMID:
16218172
18.

Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C.

Chan HL, Tsui SK, Tse CH, Ng EY, Au TC, Yuen L, Bartholomeusz A, Leung KS, Lee KH, Locarnini S, Sung JJ.

J Infect Dis. 2005 Jun 15;191(12):2022-32. Epub 2005 May 6.

PMID:
15897987
19.
20.

Transmission of G145R mutant of HBV to an unrelated contact.

Thakur V, Kazim SN, Guptan RC, Hasnain SE, Bartholomeusz A, Malhotra V, Sarin SK.

J Med Virol. 2005 May;76(1):40-6.

PMID:
15778957
21.
22.

Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation.

Hui CK, Yu J, Au WY, Zhang HY, Bartholomeusz A, Locarnini S, Kwong YL, Liang R, Lau GK.

J Clin Virol. 2005 Feb;32(2):173-8.

PMID:
15653422
23.

Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients.

Bell SJ, Lau A, Thompson A, Watson KJ, Demediuk B, Shaw G, Chen RY, Ayres A, Yuen L, Bartholomeusz A, Locarnini SA, Desmond PV.

J Clin Virol. 2005 Feb;32(2):122-7.

PMID:
15653414
24.

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ.

Antimicrob Agents Chemother. 2004 Sep;48(9):3498-507.

25.

Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains.

Wightman F, Walters T, Ayres A, Bowden S, Bartholomeusz A, Lau D, Locarnini S, Lewin SR.

J Clin Microbiol. 2004 Aug;42(8):3809-12.

26.

Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations.

Bartholomeusz A, Tehan BG, Chalmers DK.

Antivir Ther. 2004 Apr;9(2):149-60. Review.

PMID:
15134177
27.

HBV genotyping and analysis for unique mutations.

Ayres A, Locarnini S, Bartholomeusz A.

Methods Mol Med. 2004;95:125-49. No abstract available.

PMID:
14762302
28.

Hepatitis B virus genotypes: comparison of genotyping methods.

Bartholomeusz A, Schaefer S.

Rev Med Virol. 2004 Jan-Feb;14(1):3-16. Review.

PMID:
14716688
29.

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S.

Gastroenterology. 2003 Aug;125(2):292-7.

PMID:
12891527
30.

Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.

Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S, Sasadeusz J.

AIDS. 2003 Jul 25;17(11):1649-57.

PMID:
12853747
31.

Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.

Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S.

J Clin Virol. 2003 May;27(1):111-6.

PMID:
12727536
32.

Lamivudine resistant occult HBV: implications for public health?

Bowden S, Bartholomeusz A, Locarnini S.

J Hepatol. 2003 Apr;38(4):526-8. Review. No abstract available.

PMID:
12663248
33.

The hepatitis B virus and common mutants.

Locarnini S, McMillan J, Bartholomeusz A.

Semin Liver Dis. 2003 Feb;23(1):5-20. Review.

PMID:
12616447
34.

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S, Liang R.

Hepatology. 2002 Sep;36(3):702-9.

PMID:
12198664
35.

Advances in hepatitis C: what is coming in the next 5 years?

Locarnini SA, Bartholomeusz A.

J Gastroenterol Hepatol. 2002 Apr;17(4):442-7. Review.

PMID:
11982725
36.

Evolving therapies for the treatment of chronic hepatitis B virus infection.

Delaney W 4th, Bartholomeusz A, Locarnini SA.

Expert Opin Investig Drugs. 2002 Feb;11(2):169-87. Review.

PMID:
11829711
37.

Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype.

Bartholomeusz A, Locarnini S.

Hepatology. 2001 Aug;34(2):432-5. Review. No abstract available.

PMID:
11481631
38.

Targets for inhibition of hepatitis C virus replication.

Littlejohn M, Locarnini S, Bartholomeusz A.

Antivir Ther. 1998;3(Suppl 3):83-91. Review.

PMID:
10726058
39.

Flaviviridae polymerase and RNA replication.

Bartholomeusz A, Thompson P.

J Viral Hepat. 1999 Jul;6(4):261-70. Review.

PMID:
10607240
40.
42.

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.

Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, Locarnini S.

J Hepatol. 1997 May;26(5):1148-53.

PMID:
9186847
43.

Clinical experience with famciclovir against hepatitis B virus.

Bartholomeusz A, Groenen LC, Locarnini SA.

Intervirology. 1997;40(5-6):337-42. Review.

PMID:
9675638
44.

Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds.

Bartholomeusz A, Tomlinson E, Wright PJ, Birch C, Locarnini S, Weigold H, Marcuccio S, Holan G.

Antiviral Res. 1994 Aug;24(4):341-50.

PMID:
7993077
45.

Synthesis of dengue virus RNA in vitro: initiation and the involvement of proteins NS3 and NS5.

Bartholomeusz AI, Wright PJ.

Arch Virol. 1993;128(1-2):111-21.

PMID:
8418788
46.

Supplemental Content

Loading ...
Support Center